Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.4% After Analyst Downgrade
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s share price was down 6.4% during mid-day trading on Monday after Piper Sandler lowered their price target on the stock from $53.00 to $48.00.
Yahoo Finance15d
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?
When Might Dyne Therapeutics Run Out Of Money? A company's cash runway is calculated by dividing its cash hoard by its cash burn. When Dyne Therapeutics last reported its December 2024 balance ...
Morningstar15d
Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of ...
Morningstar28d
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Feb. 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with ...